Payment overview · 2025
General Payments
$565.42
32 reported records · 12 companies
Healthcare provider profile · identity verified
Kevin Scott Bodkin, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GARY, IN · NPI 1518123421
Verified facts
What the public records show
CMS Open Payments records show Kevin Scott Bodkin, D.O. received $565.42 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Epclusa as an associated drug or biological on 4711 records involving 2021 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Epclusa by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.59 | 34.1% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.04 | 12.7% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.80 | 10.4% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $43.84 | 7.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.19 | 6.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.79 | 5.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.90 | 4.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.04 | 4.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.47 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.24 | 3.2% | 1 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $17.85 | 3.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.67 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $565.42 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $85.68 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $85.68 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.92 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $58.80 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 214 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Epclusa open payments reported associated product |
CMS Open Payments — General Payments 4711 supporting records · 2021 recipient NPIs · example record 1234350832 |
Epclusa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
214 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 730 | 236 |
| Amlodipine Besylate | Amlodipine Besylate | 657 | 197 |
| Prednisone | Prednisone | 534 | 256 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 402 | 122 |
| Tizanidine Hcl | Tizanidine Hcl | 345 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 304 | 91 |
| Tramadol Hcl | Tramadol Hcl | 303 | 82 |
| Furosemide | Furosemide | 284 | 92 |
| Lisinopril | Lisinopril | 270 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 90 |
| Pregabalin | Pregabalin | 263 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 84 |
| Losartan Potassium | Losartan Potassium | 249 | 76 |
| Potassium Chloride | Potassium Chloride | 245 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 62 |
| Ozempic | Semaglutide | 214 | 44 |
| Omeprazole | Omeprazole | 212 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 198 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 67 |
| Gabapentin | Gabapentin | 189 | 71 |
| Ibuprofen | Ibuprofen | 189 | 48 |
| Metformin Hcl | Metformin Hcl | 182 | 58 |
| Alprazolam | Alprazolam | 173 | 25 |
| Alendronate Sodium | Alendronate Sodium | 145 | 42 |
| Carvedilol | Carvedilol | 145 | 49 |
| Azithromycin | Azithromycin | 141 | 109 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 44 |
| Meloxicam | Meloxicam | 119 | 39 |
| Glipizide Er | Glipizide | 113 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 38 |
| Montelukast Sodium | Montelukast Sodium | 108 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 88 | 58 |
| Allopurinol | Allopurinol | 86 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 23 |
| Eliquis | Apixaban | 78 | 25 |
| Januvia | Sitagliptin Phosphate | 78 | 18 |
| Amoxicillin | Amoxicillin | 77 | 53 |
| Clonazepam | Clonazepam | 77 | 12 |
| Simvastatin | Simvastatin | 76 | 29 |
| Glipizide | Glipizide | 74 | 24 |
| Chlorthalidone | Chlorthalidone | 71 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 18 |
| Trazodone Hcl | Trazodone Hcl | 71 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 24 |
| Spironolactone | Spironolactone | 63 | 22 |
| Famotidine | Famotidine | 62 | 23 |
| Xarelto | Rivaroxaban | 62 | 22 |
| Cephalexin | Cephalexin | 60 | 46 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 35 |
| Sucralfate | Sucralfate | 57 | 19 |
| Diazepam | Diazepam | 53 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 28 |
| Finasteride | Finasteride | 52 | 19 |
| Sertraline Hcl | Sertraline Hcl | 52 | 15 |
| Levofloxacin | Levofloxacin | 51 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 17 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 43 |
| Linzess | Linaclotide | 50 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 15 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 12 |
| Entresto | Sacubitril/Valsartan | 46 | 17 |
| Ondansetron Odt | Ondansetron | 45 | 25 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 14 |
| Lidocaine | Lidocaine | 39 | 13 |
| Valacyclovir | Valacyclovir Hcl | 39 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 36 | 12 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 13 |
| Novolog Flexpen | Insulin Aspart | 35 | 13 |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 13 |
| Anastrozole | Anastrozole | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Jardiance | Empagliflozin | 34 | 12 |
| Nitroglycerin | Nitroglycerin | 34 | 12 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 16 |
| Temazepam | Temazepam | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 30 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 17 |
| Meclizine Hcl | Meclizine Hcl | 27 | 16 |
| Mirtazapine | Mirtazapine | 27 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Metronidazole | Metronidazole | 17 | 15 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Humira(Cf) Pen | Adalimumab | 13 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Epclusa | Sofosbuvir/Velpatasvir | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $565.42 · 32 records | ABBVIE INC. | AIRSUPRA, ArdeoGraft, CARDIOMEMS, CREON, Cologuard Collection Kit, GVOKE HYPOPEN, INSPIRE, LINZESS, MAVYRET, MOUNJARO, Ozempic, PelloGraft, REXULTI, RenoGraft, Rybelsus, SurGraft, SurMatrix, The Cologuard Plus Collection Kit, VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error